167 related articles for article (PubMed ID: 9021668)
1. [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Ohuchida A; Kouchi Y; Sato S; Maeda Y
J Toxicol Sci; 1996 Nov; 21 Suppl 3():675-89. PubMed ID: 9021668
[TBL] [Abstract][Full Text] [Related]
2. [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi T; Tanaka G; Irimura K; Hirota T; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():495-504. PubMed ID: 9021658
[TBL] [Abstract][Full Text] [Related]
3. Mutagenicity tests of mofezolac (N-22).
Ohuchida A; Furukawa A
J Toxicol Sci; 1990 Jun; 15 Suppl 2():239-51. PubMed ID: 2231792
[TBL] [Abstract][Full Text] [Related]
4. Mutagenicity tests on propiverine hydrochloride.
Ohuchida A; Furukawa A
J Toxicol Sci; 1989 May; 14(2):131-41. PubMed ID: 2778853
[TBL] [Abstract][Full Text] [Related]
5. Reverse mutation tests in Salmonella typhimurium and chromosomal aberration tests in mammalian cells in culture on fluorinated pyrimidine derivatives.
Yajima N; Kondo K; Morita K
Mutat Res; 1981 Mar; 88(3):241-54. PubMed ID: 6454840
[TBL] [Abstract][Full Text] [Related]
6. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Hayashi T; Yamaguchi S; Kito S; Tanaka G; Kurokawa K; Hirota T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():527-44. PubMed ID: 9021660
[TBL] [Abstract][Full Text] [Related]
7. [A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Hayashi T; Hasegawa H; Tanaka G; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():505-26. PubMed ID: 9021659
[TBL] [Abstract][Full Text] [Related]
8. [Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)].
Iwakura K; Tamura H; Yamashita Y; Watanabe M; Sumi N; Shindo Y; Ando M; Kojima M
J Toxicol Sci; 1996 Jun; 21 Suppl 1():241-57. PubMed ID: 8709165
[TBL] [Abstract][Full Text] [Related]
9. Mutagenicity of carbon tetrachloride and chloroform in Salmonella typhimurium TA98, TA100, TA1535, and TA1537, and Escherichia coli WP2uvrA/pKM101 and WP2/pKM101, using a gas exposure method.
Araki A; Kamigaito N; Sasaki T; Matsushima T
Environ Mol Mutagen; 2004; 43(2):128-33. PubMed ID: 14991753
[TBL] [Abstract][Full Text] [Related]
10. [Mutagenicity tests of tazobactam/piperacillin, tazobactam and piperacillin].
Ohuchida A; Taniguti A; Kouchi Y; Maeda Y; Kashihara A; Omae S
J Toxicol Sci; 1994 Oct; 19 Suppl 2():263-80. PubMed ID: 7830291
[TBL] [Abstract][Full Text] [Related]
11. Mutagenicity test of cefodizime sodium.
Ohuchida A; Yoshida R
J Toxicol Sci; 1988 Jun; 13 Suppl 1():245-56. PubMed ID: 3050144
[TBL] [Abstract][Full Text] [Related]
12. Genotoxicity assessment of pirmenol, a new antiarrhythmic drug.
Ciaravino V; Kropko ML; Krishna G; Monteith DK; Theiss JC
Mutat Res; 1992; 280(3):205-14. PubMed ID: 1381484
[TBL] [Abstract][Full Text] [Related]
13. Microbial mutagenicity and in vitro chromosome aberration induction by FK973, a new antitumor agent.
Hirai O; Miyamae Y; Hattori Y; Takashima M; Miyamoto A; Zaizen K; Mine Y
Mutat Res; 1994 Jun; 324(1-2):43-50. PubMed ID: 7515469
[TBL] [Abstract][Full Text] [Related]
14. [Mutagenicity studies of RCC-36, the active metabolite of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a novel drug for urinary frequency and incontinence].
Tamura H; Yamashita Y; Kitayama E; Iwakura K; Watanabe M; Sumi N
J Toxicol Sci; 1997 Apr; 22 Suppl 1():263-74. PubMed ID: 9170614
[TBL] [Abstract][Full Text] [Related]
15. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
16. [Mutagenicity tests of suplatast tosilate (IPD-1151T)].
Ohuchida A; Furukawa A; Sato S; Maeda Y; Kashihara A; Mizumoto T; Yoshida R
J Toxicol Sci; 1992 May; 17 Suppl 2():207-20. PubMed ID: 1321262
[TBL] [Abstract][Full Text] [Related]
17. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
18. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
Korenaga D; Honda M; Yasuda M; Inutsuka S; Nozoe T; Tashiro H
Eur Surg Res; 2002; 34(5):351-6. PubMed ID: 12364819
[TBL] [Abstract][Full Text] [Related]
19. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
20. [Genotoxicity studies of cefmatilen hydrochloride hydrate (S-1090)].
Kondo K; Takase S; Nishimoto Y; Miyajima H; Shiratori O; Miyake Y
J Toxicol Sci; 2001 May; 26 Suppl 1():243-54. PubMed ID: 11400316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
